Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity.
about
Drug-induced liver injury: present and futureAssociation Between IL-4 Polymorphisms and Risk of Liver Disease: An Updated Meta-AnalysisNew genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivityIdiosyncratic adverse drug reactions: current conceptsDrug-induced hepatotoxicity: metabolic, genetic and immunological basisPharmacogenomics of adverse drug reactionsThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityProfiles of serum cytokines in acute drug-induced liver injury and their prognostic significanceAnalysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control studyIntrinsic versus idiosyncratic drug-induced hepatotoxicity--two villains or one?Mass spectrometric characterization of circulating covalent protein adducts derived from a drug acyl glucuronide metabolite: multiple albumin adductions in diclofenac patients.Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicityRole of IL-4 gene polymorphisms in HBV-related hepatocellular carcinoma in a Chinese population.Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients.Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1.Risk factors for idiosyncratic drug-induced liver injury.Thymic stromal lymphopoietin and interleukin-4 mediate the pathogenesis of halothane-induced liver injury in mice.Endogenous interleukin-4 regulates glutathione synthesis following acetaminophen-induced liver injury in miceGenetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)Idiosyncratic drug hepatotoxicity.Mechanisms of drug-induced liver injury.Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications.Investigations toward enhanced understanding of hepatic idiosyncratic drug reactions.Eosinophils mediate the pathogenesis of halothane-induced liver injury in miceSuppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a reviewImmunogenomics reveal molecular circuits of diclofenac induced liver injury in miceAssessment of drug-induced liver injury in clinical practice.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group.Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.Current concepts of mechanisms in drug-induced hepatotoxicity.Changes in IL-2 and IL-10 during Chronic Administration of Isoniazid, Nevirapine, and Paracetamol in Rats.Drug-induced liver injury: insights from genetic studies.Biomarkers for drug-induced liver injury.Muscle Injury After Intramuscular Administration of Diclofenac: A Case Report Supported by Magnetic Resonance Imaging.Drug-induced liver injury: past, present and future.Pharmacogenetics of drug-induced liver injury.Hepatotoxicity related to antirheumatic drugs.Drug-induced autoimmune-like hepatitis.Managing the challenge of chemically reactive metabolites in drug development.
P2860
Q24630227-3478C706-34B2-4713-8FC8-AC4D582021A6Q26786158-45712B9A-EBDC-440D-B718-611A10CB0643Q26800976-0A2C4DF0-200D-4058-BCD9-D1BE9C71B8BBQ26824391-8ED1D50E-5414-4724-A6C8-1C6CAE5A02B1Q26991809-ACD1501D-EF97-431B-A36A-EA44A9F8D71AQ27015820-0121ABA2-128D-46A6-8EA8-F2B9D49FC324Q28080256-62D9972C-7700-4AFE-B311-87ECEB1CF77FQ28538041-0A29CDAA-29D8-4ACD-9D66-C8D39C58CA0AQ28544718-D135BF30-DF1B-4192-84FD-C656E454A40FQ33714926-0A524E15-AD05-4E4D-99F8-CD524B329EBEQ33944025-6101D47A-5009-44A3-A75C-D4A3D0300910Q34200596-B85CB010-1465-46A1-A462-B4EF3AE28C9CQ34309028-1B00CE37-6492-46F6-B76A-167B116C90B6Q34473555-7E717742-84FB-4768-A3FF-FBCFAF882319Q35135974-AEBABB33-A752-4CE0-AD95-46AE45F7446DQ35168108-2B7E2C01-6764-4A6E-8B8C-9AE49CBFF3EBQ35673199-D370F299-9779-4532-9541-859771931657Q35675464-9C0B058B-91B7-4DB1-BF9A-BFAC0C873803Q36052505-59B1F84E-C487-4FDE-A01B-3DC1648ADC10Q36148442-891F1CDF-B576-42CB-8CBD-7A789CC2CE60Q36439183-8D418CEB-785C-44F3-8C81-F173014CB0ABQ36479455-49587CBC-4E71-4654-B716-C87210139FDBQ36662857-EFDDB608-D4CB-431A-B170-A97E4A05C145Q36724588-6DF5C546-D0B1-4AAF-82CB-8AD6E463023BQ36851882-AD0F3E7D-17AD-453F-8D50-02A56683BFB9Q37046776-04729640-5E7F-4593-B2E1-E1D48D3695C8Q37114105-ABDF04B6-B133-44B1-903B-7797311649E2Q37121662-D6710A8F-8ABE-4785-8352-C2F31C49FF99Q37142641-051F0CEA-3D96-4E20-9F9A-74435ABA5307Q37391731-1F7D59B5-439F-4530-AE09-99131B55599CQ37394799-D054B9F8-1B3A-4109-A821-E1F47A6B8A0CQ37470803-F3473414-7B04-4141-AA1F-689BAF3C26DDQ37598897-369B2BF3-203F-4359-8BD4-22D5AF799E2DQ37720754-4860F43B-8832-4417-A5BF-FAE066EA6A49Q37720979-E4360DC5-0D29-4638-B5B8-AF96F1443AA4Q37736444-848FBFD8-2E9D-4F3D-8F23-65AE431C1C6FQ37770487-B8051E46-D201-428F-8F0F-1165C2FD9A63Q37832129-9CEA7A5D-EE20-4822-B083-08CD7A883531Q37843783-718ABB86-D498-4FE1-A49D-FAB767CEA158Q37860142-3CF86CFE-DF37-422C-BE06-BA2507E4DD6A
P2860
Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Hepatic adducts, circulating a ...... ith diclofenac hepatotoxicity.
@en
Hepatic adducts, circulating a ...... ith diclofenac hepatotoxicity.
@nl
type
label
Hepatic adducts, circulating a ...... ith diclofenac hepatotoxicity.
@en
Hepatic adducts, circulating a ...... ith diclofenac hepatotoxicity.
@nl
prefLabel
Hepatic adducts, circulating a ...... ith diclofenac hepatotoxicity.
@en
Hepatic adducts, circulating a ...... ith diclofenac hepatotoxicity.
@nl
P2093
P50
P921
P356
P1433
P1476
Hepatic adducts, circulating a ...... ith diclofenac hepatotoxicity.
@en
P2093
Christopher P Day
Graeme Alexander
John Caldwell
Julian B S Leathart
Lesley Ramsay
Nhareet Sonchit
P304
P356
10.1002/HEP.20205
P407
P577
2004-05-01T00:00:00Z